Verproside |
Catalog No.GC37898 |
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 50932-20-2
Sample solution is provided at 25 µL, 10mM.
Verproside, a catalpol derivative iridoid glycoside isolated from the genus Pseudolysimachion, represses TNF-α -induced MUC5AC expression by inhibiting NF-κB activation via the IKK/IκB signaling cascade. Verproside has potent anti-inflammatory, antioxidant, antinociceptive activities and ir is a potent anti-asthmatic/COPD drug candidate in vivo[1]. NF-κB TNF-α IKK
Verproside (2.5-20 μM; for 2 hours) markedly reduces phosphorylation levels of IKKα/β, IκBα, and TAK1 in the 5-20 μM range[1]. Western Blot Analysis[1] Cell Line: NCI-H292 cells
Verproside (Intragastrically; 30 mg/kg; 48 hours) significantly reduces the immunoglobulin E (IgE) levels of verproside-treated mice[2]. Animal Model: Specific pathogen-free female BALB/c mice aged 8-10 weeks[2]
[1]. Lee SU, et al. Verproside inhibits TNF-α-induced MUC5AC expression through suppression of the TNF-α/NF-κB pathway in human airway epithelial cells. Cytokine. 2016 Jan;77:168-75. [2]. Oh SR, et al. Suppressive effect of verproside isolated from Pseudolysimachion longifolium on airway inflammation in a mouse model of allergic asthma. Int Immunopharmacol. 2006 Jun;6(6):978-86. Epub 2006 Feb 10.
Average Rating: 5
(Based on Reviews and 5 reference(s) in Google Scholar.)GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *